Â鶹´«Ã½

Skip to main content

Displaying 61 - 71 of 71

Competition Matters

MMA Reports: No tricks or treats—just facts

Date
With the passage of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), Congress required pharmaceutical companies to file certain patent settlement agreements with the...
Advanced Page

Pay for Delay

Pay-for-Delay: When Drug Companies Agree Not to Compete One of the FTC’s top priorities in recent years has been to oppose a costly legal tactic that more and more branded drug manufacturers have been...
Competition Matters

Quo Vadis Post-Actavis?

Date
For more than 15 years, one of the FTC’s top priorities has been to put an end to anticompetitive reverse-payment settlements between brand-name drug makers and their potential generic rivals. In our...